I-omics Biotech has launched the sharpening stone series of automated grinding instruments. This device, with its outstanding performance and innovative automation technology, will bring unprecedented changes to the global biological sample analysis industry, enabling complex sample grinding to be achieved through unattended automation. Combined with I-omics Biotech for sealing, peeling, pipetting, centrifuging, and filtration, it ultimately realizes the ultimate goal of sample in, result out fo

BackgroundSpring and autumn are crucial seasons for preventing the occurrence of animal diseases, serving as key periods to prevent major outbreaks. Proper animal disease prevention during these seasons can effectively reduce the incidence of animal diseases, benefiting farmers' income growth and agricultural efficiency, ensuring food safety, maintaining public health security, preventing zoonotic diseases, and promoting the healthy and orderly development of animal husbandry. Traditional ma

In April 2024, the self-developed nucleic acid extraction kit automatic production line of I-omics Biotechsuccessfully completed the installation and debugging work for a listed company on the science and Technology Innovation Board, which further improved the production efficiency of molecular diagnostic reagent production for the listed company and better guaranteed the product quality.Performance features: 1.The system integrates advanced precision mechanical automation control technology,

From January 4 to 6, the 3rd Sanya International Congress of Seed Industry Scientists and 2024 International Seed Industry Science and Technology Expo was held in Sanya. This year's conference invited more than 30 Chinese and foreign academicians, more than 100 college and university presidents and deans of the Academy of Agricultural Sciences as guests to attend the conference and make reports. In the main forum, Li Jiayang, academician of the Chinese Academy of Sciences and director of Yaz

In recent years, the progress of biotechnology and computer technology has led to the rapid development of breeding technology, and agricultural developed countries have entered the breeding 4.0 era characterized by biotechnology + artificial intelligence + big data, and continue to focus on a new generation of revolutionary and disruptive technologies. The international seed industry has entered a period of opportunity to seize the strategic high ground and economic growth point as the goal, sh

Shanghai, December 25, 2023- Today, Shanghai I-omics Biotech Co., Ltd. (hereinafter referred to as "I-omics Biotech") is honored to announce that the company has successfully been recognized as a "high-tech enterprise" in Shanghai for the year 2023. The achievement of this honor marks a significant achievement of I-omics Biotech in the field of technological innovation, which has been highly recognized by the industry and government. The recognition of "high-tech enterprises" in Shanghai is a strict evaluation of enterprises in terms of technological research and development, innovation capabilities, and future development potential. With its outstanding research and development capabilities and innovative achievements, I-omics Biotech has successfully passed multiple rounds of screening and been selected as one of the "High tech Enterprises" in Shanghai for 2023.

Shanghai, November 1, 2023- Today, Shanghai I-omics Biotech Co., Ltd. announced that the company is honored to be included in the list of specialized, refined, and new small and medium-sized enterprises in Shanghai. This is a high recognition of the company's innovation and professional development in the industry, and also a commendation from the Shanghai Municipal Government for the company's technological strength. The recognition of specialized, refined, distinctive, and innovative small and medium-sized enterprises in Shanghai is an important certification by the Shanghai Municipal Government for enterprises that have outstanding performance in specialization, refinement, uniqueness, and innovation. I-omics Biotech, with its outstanding achievements in the field of biotechnology research and development, has successfully entered this list, demonstrating the company's strong strength in technological innovation and market competition. At present, the instruments and equipment pr

MDPro 400 is a high-throughput platform launched for hemagglutination/hemoinhibition detection, drug discovery, antibody screening, and diagnostic reagent formulation optimization, which can process 1-4 microplates at the same time. For gradient dilution, it can process more than 320 microplates in 8 hours and obtain nearly 30,000+ reagent combinations with different concentration combination, which greatly accelerates the speed of research. For antibody and diagnostic reagent optimization, the MDPro400 high-throughput platform can increase R&D speed by more than 10 times and expand the screening range by more than 10 times, which greatly improves the R&D efficiency and the success rate. It is a valuable platform for dianostic technicians and research scientists.